Methiopropamine
Viewing r1 — May 12, 2026
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MPA (methiopropamine) is a synthetic stimulant of the thiophene class. It is the direct thiophene structural analog of methamphetamine, roughly five times less potent in animal models.[1] MPA is a norepinephrine-dopamine reuptake inhibitor, producing its effects by elevating catecholamine levels in the brain's reward and arousal circuits.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized in 1942 as part of a University of Michigan program exploring modified amphetamine ring systems,[2] MPA attracted no therapeutic interest and was forgotten for nearly seven decades. It resurfaced in late 2010 on the UK "legal high" market, sold under brand names like "Synthacaine" as an ostensible cocaine substitute.[3] MPA is now a controlled substance in the United States, United Kingdom, Germany, and China, with the WHO recommending international scheduling.[4]
Subjective effects include enhanced wakefulness, sustained attention, mood elevation, and physical stimulation. The experience is characteristically functional rather than euphoric — a steady, methylphenidate-like focus without the hedonic rush or empathogenic warmth of more potent stimulants.[3] Fatigue, irritability, low mood on the comedown, and compulsive redosing are common unsought effects.
MPA carries significant dependence potential — locomotor sensitization and structural brain changes develop after as few as four doses in animals[5] — and no lethal dose has been established in any species. A steep dose-response curve narrows the margin between mild stimulation and cardiovascular toxicity; chronic exposure in mice produced myocardial damage and 40% sudden death without behavioral warning signs.[6] No controlled human studies exist; the current understanding rests on rodent pharmacology, clinical case reports, and forensic data.
History[edit]
History
Synthesis and Early Obscurity
MPA was first prepared in 1942 by Frederick F. Blicke and John H. Burckhalter at the University of Michigan, as part of a systematic program replacing the phenyl ring in amphetamine-type stimulants with heterocyclic alternatives.[2] The compound — methamphetamine with a thiophene ring swapped for its benzene ring — showed lower stimulant potency than its parent and offered no clinical advantage over established wartime stimulants. No therapeutic development followed, and MPA remained a footnote in the chemical literature for nearly seven decades.
Emergence on the NPS Market
MPA resurfaced in December 2010 on the UK "legal high" market, sold under branded product names including "Blow," "Synthacaine," and "Bomb".[3] "Synthacaine" — the most widely distributed brand — was found to contain a mixture of MPA and 2-aminoindane, marketed explicitly as a cocaine substitute.[7] Clinical detection of MPA use was first reported in 2011,[8] and by 2012 the compound was detected in anonymous pooled urine samples from portable urinals in central London, confirming significant uptake among recreational users.[9]
Regulatory Response
The UK Advisory Council on the Misuse of Drugs recommended banning MPA in November 2015, and a Temporary Class Drug Order followed the same month; permanent Class B status took effect in November 2017.[3] The United States placed MPA in Schedule I in December 2022.[10] The WHO Expert Committee on Drug Dependence subsequently recommended placement in Schedule II of the 1971 UN Convention on Psychotropic Substances.[4]
The name "methiopropamine" derives from the compound's structural identity: "methio-" for the thiophene ring that replaces methamphetamine's benzene, and "-propamine" for the propylamine side chain shared with its parent compound. On the NPS market, MPA was rarely sold under its chemical name — branded products like "Synthacaine" positioned it as a legal cocaine alternative, a framing that shaped both its user base and its regulatory trajectory. The first published case of acute intoxication, in 2016, involved a patient who consumed "Synthacaine" and presented with paranoid delusions and hallucinations.[11]
Chemistry[edit]
Chemistry
Structural Class
MPA belongs to the thiophene class of substituted amphetamines, in which the six-membered benzene ring of methamphetamine is replaced by a five-membered, sulfur-containing thiophene ring at the 2-position. This bioisosteric swap preserves the molecule's overall shape and lipophilicity while altering its electronic properties and metabolic susceptibility. The amine side chain is identical to methamphetamine's: an α-methyl group (conferring chirality) and an N-methyl group (distinguishing MPA from the primary amine structural analog thiopropamine).
Molecular Properties
| Molecular formula | C₈H₁₃NS |
| Molecular weight | 155.26 g/mol (free base); 191.72 g/mol (HCl salt) |
Stereochemistry
The α-carbon of the propylamine side chain is a chiral center, giving rise to (R)- and (S)-enantiomers. All analyzed preparations and seized samples to date are racemic mixtures.[12] No study has separated and tested the individual enantiomers. By analogy with methamphetamine — where the (S)-(+) isomer is the substantially more potent CNS stimulant — differential enantiomeric activity is plausible but unconfirmed.
Physical Properties
The free base is an off-white to yellowish powder with a bitter taste and a faint aniseed-like odor.[3] The hydrochloride salt is soluble in ethanol (~20 mg/mL), DMSO (~10 mg/mL), and DMF (~20 mg/mL).[12] No published data exist on aqueous solubility, pKa, logP, or long-term storage stability.
Pharmacology[edit]
Pharmacology
Mechanism of Action
MPA acts primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI), blocking the transporters that clear norepinephrine and dopamine from the synapse. Norepinephrine reuptake is inhibited at slightly lower concentrations than dopamine reuptake; SERT inhibition is negligible at typical doses, requiring roughly 50-fold higher concentrations.[1]
This profile makes MPA mechanistically closer to methylphenidate than to amphetamine. Both methylphenidate and MPA block catecholamine reuptake; amphetamine, by contrast, actively releases stored monoamines into the synapse — a distinction that accounts for amphetamine's greater potency and subjective intensity. Multiple independent studies confirm MPA as a reuptake inhibitor rather than a releasing agent.[1][13]
Relative to methamphetamine, MPA is approximately five times less potent in rodent locomotor assays.[1] Relative to dextroamphetamine, MPA is roughly one-third as potent at the NET and one-fifth as potent at the DAT.[12]
Pharmacokinetics
No controlled human pharmacokinetic studies have been published. In mice, MPA administered by injection was rapidly distributed to blood and brain.[1] The only human plasma measurement comes from a single case report: 14 ng/mL at 13 hours after emergency presentation following "Synthacaine" consumption[11] — a value that cannot be interpreted without established concentration-effect relationships.
MPA is metabolized via N-demethylation and aromatic hydroxylation.[14] The specific liver enzymes responsible have not been identified; CYP2D6 involvement is inferred from structural similarity to methamphetamine but is unconfirmed.[14] inferred Oral bioavailability, half-life, and volume of distribution in humans remain entirely unknown.
Neuroscience[edit]
Neuroscience
Where It Acts
By blocking dopamine and norepinephrine reuptake, MPA elevates catecholamine levels in the nucleus accumbens and prefrontal cortex — the brain regions that underlie reward, motivation, and sustained attention. Elevated dopamine in the nucleus accumbens produces the reinforcing and mildly euphoric properties; elevated norepinephrine in cortical regions drives the wakefulness, focus, and sympathomimetic arousal that define MPA's functional character.
Repeated MPA exposure produces structural changes in the nucleus accumbens: after as few as four doses in rats, dendritic spine density increased, with a preferential growth of immature spines.[5] This pattern — shared with amphetamine and cocaine — is a structural signature of the brain progressively wiring in drug-seeking motivation.
Why It Matters
The locomotor sensitization and structural brain changes observed with MPA[15][5] map onto the incentive sensitization framework: repeated exposure progressively amplifies the motivational pull toward the drug ("wanting") even as subjective pleasure ("liking") plateaus or diminishes. This predicts that compulsive redosing — widely reported by users — intensifies with repeated use despite limited euphoria.
At the molecular level, MPA-induced neurotoxicity in mice follows an oxidative-stress-to-cell-death cascade: elevated reactive oxygen species, inflammatory microglial activation, and reduced dopamine system markers.[16] This pattern mirrors methamphetamine neurotoxicity, though higher doses are required, consistent with MPA's lower potency.
Whether MPA's individual enantiomers differ in potency — as methamphetamine's do — has never been tested. The mouse neurotoxicity data are difficult to extrapolate to humans without species-specific pharmacokinetic data; whether cumulative recreational-dose exposure causes subclinical dopaminergic damage is unknown.
Subjective Effects[edit]
Subjective Effects
MPA delivers a functional, task-oriented stimulation rather than the euphoric surge associated with amphetamine or cocaine. At lower doses, the experience centers on sustained wakefulness and sharpened focus, with modest mood elevation and mild physical energy. As dose increases, somatic stimulation intensifies — elevated heart rate, jaw tension, appetite suppression — and the steep dose-response curve documented in animal models[1] suggests this escalation may be abrupt rather than gradual. Set and setting exert moderate influence: the functional character lends itself to task-oriented contexts, but stimulant-typical anxiety amplification can sharpen in stressful or socially charged environments.
Among stimulants, MPA is most frequently compared to methylphenidate — users consistently describe a "functional" rather than "recreational" character at typical doses.[3] It lacks the serotonergic warmth of MDMA and the dopaminergic punch of amphetamine, sitting in a quieter register that nonetheless carries a notable tendency toward compulsive redosing — a pattern more suggestive of abuse liability than the subjective mildness might imply.
Effect Grid
Clear stimulant effects establish themselves: sustained wakefulness, focus enhancement, and mild cognitive euphoria. Thought acceleration and thought organization improve task engagement. Analysis enhancement is noticeable. Motivation enhancement supports sustained productivity. Music enhancement may be subtly present.
Appetite suppression is moderate and reliable. Stimulation is clearly perceptible — increased energy and physical alertness without the intensity of amphetamine. Heart rate elevation is common. Spontaneous body sensations and mild temperature dysregulation may emerge. Bruxism and excessive sweating are possible but typically mild.
Compulsive redosing urge may emerge at this tier — users frequently describe wanting to sustain the functional stimulation. Oral duration is 6–10 hours. Insomnia is likely if taken in the afternoon or evening. Comedown involves mild fatigue, irritability, and low mood.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual processing acceleration · Visual acuity enhancement · Auditory hallucinations · External hallucinations · Shadow people
Shadow people
Dry mouth · Insomnia · Pupil dilation · Dehydration sensation · Heart rate perception changes · Physical fatigue · Restlessness · Excessive sweating · Body high · Muscle tension · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Bruxism · Bodily lightness · Headache · Nausea · Tingling / electric sensations · Trembling · Motor control enhancement · Constipation · Dizziness · Nasal congestion · Tactile euphoria · Abnormal heartbeat · Pain suppression · Vibrations / buzzing · Vomiting · Tactile hallucination
Dehydration sensation · Heart rate perception changes · Physical fatigue · Restlessness · Excessive sweating · Body high · Muscle tension · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Bruxism · Bodily lightness · Headache · Nausea · Tingling / electric sensations · Trembling · Motor control enhancement · Constipation · Dizziness · Nasal congestion · Tactile euphoria · Pain suppression · Vibrations / buzzing · Vomiting · Tactile hallucination
Immersion enhancement · Pattern recognition enhancement · Focus enhancement · Analysis enhancement · Motivation enhancement · Information processing enhancement · Thought organization · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Language enhancement · Novelty enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Memory enhancement · Motivation suppression · Cognitive impairment · Conceptual thinking · Confusion · Creativity suppression · Multiple thought streams · Suggestibility suppression · Thought deceleration · Thought disorganization · Thought loops
Motivation enhancement · Information processing enhancement · Thought organization · Aesthetic enhancement · Cognitive dysphoria · Cognitive flexibility · Language enhancement · Novelty enhancement · Thought connectivity · Creativity enhancement · Humor enhancement · Memory enhancement · Motivation suppression · Cognitive impairment · Conceptual thinking · Confusion · Creativity suppression · Multiple thought streams · Suggestibility suppression · Thought deceleration · Thought disorganization · Thought loops
Anhedonia · Emotional enhancement · Dysphoria · Emotional lability · Mania
Emotional lability
Ego inflation · Sociability enhancement · Flow state · Automaticity · Social connection · Self-control enhancement
Social connection · Self-control enhancement
Timeline
Gradual awareness of mild stimulation. Slight increase in alertness and wakefulness without clear euphoria.
Building wakefulness and focus. Mild body stimulation emerges. Appetite suppression begins.
Full stimulant effect — sustained attention, wakefulness, appetite suppression, mild cognitive euphoria. Task engagement enhanced. Compulsive redosing urge may emerge.
Stimulation sustains at reduced intensity. Focus persists but euphoria fades. Restlessness may replace productive engagement.
Gradual diminishment of stimulation. Emerging fatigue and irritability. Appetite begins to return.
Residual wakefulness, low mood, tiredness, possible headache. Cognitive fatigue and motivation suppression may persist.
⚠ Avoid driving during afterglow — residual cognitive fatigue and irritability may impair reaction time.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · methylphenidate
Toxicity
Acute Toxicity
No lethal dose has been established for MPA in any species, and no controlled human toxicity data exist. The steep dose-response curve in rodents — where effects escalated sharply within a narrow dosage range[1] — suggests a thin margin between a behaviorally active dose and a dangerous one.
At higher doses in mice, MPA produced increased heart rate, elevated blood pressure, decreased oxygen saturation, hypothermia, and motor stereotypies.[13] At lower doses closer to typical human use, no hazardous effects were observed — a deceptive "gray zone" that may encourage dose escalation.[13]
Cardiovascular Toxicity
Cardiovascular damage is the primary organ-system concern. Chronic MPA exposure in mice produced heart muscle damage consistent with repeated oxygen deprivation, alongside tissue death in the kidneys and gastrointestinal tract.[6] Most critically, 40% of chronically treated mice died suddenly, attributed to vasoconstriction-induced cardiovascular events — and body weight, food intake, and coordination showed no decline beforehand, meaning organ damage progressed without visible warning.[6]
In hospitalized human cases, rapid heart rate was the most common finding (91% of 11 confirmed cases).[8] Elevated creatine kinase — a marker of muscle breakdown — appeared in 64% of hospitalized patients, though most cases involved multiple substances.[8]
Injection-Related Harm
Intravenous MPA use has been documented in Scotland, where it was linked to Staphylococcus aureus blood infections, heart valve infections, and septic emboli in prisoners.[18]
Post-Mortem Data
MPA was detected in one polydrug fatality at approximately 2.2 µg/L in femoral blood; death was attributed to positional asphyxia during co-intoxication with designer benzodiazepines and stimulants, and MPA's specific contribution remains unclear.[19]
Psychological Risks
Acute psychological toxicity is well-documented in clinical reports. Among hospitalized patients, confusion (64%), agitation (64%), and hallucinations (45%) were prevalent.[8] One case report described paranoid delusions, auditory and visual hallucinations, and incoherent speech after consuming "Synthacaine".[11] One patient required transfer to inpatient psychiatric care.[8]
In mice, seven days of repeated MPA exposure impaired recognition memory, working memory, and reference memory, with deficits persisting at least 24 hours after the last dose.[17] Low-normal doses produced aggressive behavior, with intensity increasing upon repeated exposure.[20]
No published data address long-term psychiatric consequences such as prolonged psychosis or chronic mood disturbance.
Tolerance and Dependence
No controlled human studies of tolerance or dependence have been conducted.
Tolerance develops with repeated use. Community estimates suggest a tolerance half-life of approximately 5 days, though no published study confirms these figures. safety citation needed Cross-tolerance with other dopamine-active stimulants (amphetamine, methylphenidate) is expected but untested.
Dependence liability is supported by multiple lines of animal evidence: locomotor sensitization after as few as four doses,[15] structural rewiring in the brain's reward center after four injections,[5] cognitive impairment persisting after cessation,[17] and frequent user reports of compulsive redosing. The WHO concluded that MPA has abuse potential and ill-effects comparable to Schedule II substances.[4]
No physical withdrawal has been described. Psychological withdrawal — fatigue, anhedonia, low mood, irritability — is reported by users but has not been systematically studied.
Drug Interactions
Serotonergic Combinations
Although MPA's serotonin activity is negligible at typical doses,[1] combining it with potent serotonergic agents creates additive risk. Harm reduction organizations warn that combining MPA with MDAI or 5-IAI may produce serotonin syndrome — symptoms including dangerously high body temperature, elevated blood pressure, dilated pupils, and muscle breakdown potentially leading to fatal kidney failure.[3] safety citation needed
MDMA co-administration is classified as dangerous. MDMA's potent serotonin release combined with MPA's catecholamine reuptake inhibitor creates credible risk from elevated serotonin tone and additive cardiovascular strain. safety citation needed
Tramadol
The MPA + tramadol combination carries lethal risk. Tramadol's serotonin reuptake inhibition layered onto MPA's catecholamine blockade could precipitate serotonin syndrome, compounded by additive cardiovascular strain. No specific case report confirms this interaction, but the pharmacological basis is strong. safety citation needed
Alcohol
No published data exist on MPA + alcohol interaction. Standard stimulant-depressant concerns apply: MPA may mask alcohol's sedative effects, leading to increased consumption and additive cardiovascular stress.
CYP-Mediated Interactions
MPA is metabolized via CYP enzymes.[14] If CYP2D6 is the primary enzyme (inferred but unconfirmed), drugs that inhibit CYP2D6 — including fluoxetine, paroxetine, and bupropion — could elevate MPA levels in the blood. Genetic CYP2D6 poor metabolizer status would produce similar effects. inferred
Contraindications
No substance-specific contraindication studies exist. The following are inferred from MPA's pharmacological profile and documented toxicity:
Absolute contraindications:
- Pre-existing heart conditions (coronary artery disease, cardiomyopathy, arrhythmias, uncontrolled high blood pressure): MPA produces rapid heart rate in 91% of hospitalized cases,[8] blood vessel constriction, and heart muscle damage in chronic animal models.[6]
- Concurrent MAOI use: monoamine oxidase inhibitors combined with a catecholamine reuptake inhibitor risk hypertensive crisis. inferred
Relative contraindications:
- Seizure disorders: stimulants as a class lower seizure threshold. inferred
- Psychotic disorders or bipolar disorder: acute psychosis, paranoid delusions, and hallucinations are documented in MPA intoxication.[8][11]
- Kidney impairment: muscle breakdown (elevated CK in 64% of hospitalized cases) and kidney tissue death in chronic animal models.[8][6]
- Pregnancy and lactation: no reproductive toxicity data exist; catecholaminergic stimulants are generally contraindicated due to blood vessel constriction and developmental risks. inferred
- Concurrent serotonergic medication (SSRIs, SNRIs, MAOIs, tramadol): serotonin toxicity risk, particularly at higher doses where MPA's SERT inhibition may become relevant.
Harm Reduction[edit]
Harm Reduction
Forms & Identification
MPA typically circulates as a white to off-white powder, though yellowish batches with a faint aniseed-like odor have been documented.[3] The compound has a history of being sold in branded products — most notably "Synthacaine" — that frequently contain other active substances, including 2-aminoindane.[7] Reagent testing confirms chemical identity but cannot verify purity or detect all adulterants; given MPA's track record of being sold as mixtures, a positive test tells you what is present, not what else might be.
Set & Setting
MPA's functional, low-euphoria character makes it less likely to produce acute psychological crises than more potent stimulants, but agitation, paranoia, and hallucinations are documented at higher doses.[8] A calm, familiar environment with trusted company reduces the likelihood of anxiety escalation. Plan sleep well in advance — the stimulant tail makes it difficult to sleep if dosing occurs in the afternoon or evening.
Guidelines
- Test every batch. Branded NPS products have repeatedly contained substances other than what is advertised. Reagent testing is a minimum; quantitative analysis (e.g. FTIR or lab testing services) provides more reliable identification.
- Start low. The steep dose-response curve means the gap between a mild experience and a dangerous one is narrower than for most stimulants. Titrate upward slowly, particularly with a new batch.
- Avoid redosing. Compulsive redosing is one of MPA's most consistently reported features. Set a dose limit before the session and use a timer to enforce spacing.
- Stay hydrated and eat. Stimulant appetite suppression and fluid neglect compound cardiovascular strain. Drink water regularly and eat a meal before dosing.
- Avoid injection. Intravenous MPA use carries documented risks of serious bacterial infections including heart valve infections.[18]
Aftercare & Integration
MPA's comedown typically involves fatigue, low mood, and irritability. Prioritize sleep — a full night is the single most effective recovery measure. Eat nutrient-dense food, particularly protein and complex carbohydrates, to support neurotransmitter replenishment. Avoid caffeine or other stimulants during the comedown, which extend cardiovascular strain without meaningfully improving mood.
If low mood or irritability persists beyond 48–72 hours, or if cravings to redose are strong, consider this a signal that use patterns may be escalating. Track frequency and dose over time; the animal evidence for rapid dependence development[5] suggests that motivational patterns can establish faster than subjective experience indicates.
Recovery & Support
MPA has no characterized physical withdrawal, but psychological dependence — driven by compulsive redosing and the motivational rewiring documented in animal models — can be difficult to interrupt without support. If use has become regular or difficult to stop, professional support from an addiction counselor or substance use service is appropriate. SMART Recovery and similar evidence-based programs offer structured frameworks for stimulant dependence. In the UK, FRANK (0300 123 6600) and in the US, SAMHSA's National Helpline (1-800-662-4357) provide confidential guidance and referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
Uncomfortable but manageable: jitteriness, mild anxiety, elevated heart rate, jaw tension. These are unpleasant but not dangerous at typical doses.
Seek immediate help if: chest pain, seizure, loss of consciousness, extremely rapid or irregular heartbeat, confusion with paranoid delusions or hallucinations, body temperature hot to the touch through clothing, or signs of muscle breakdown (dark urine, severe muscle pain).
Immediate steps:
- 1. Call emergency services.
- 2. Move the person to a cool, quiet area. Remove excess clothing if overheating.
- 3. Do not restrain unless there is immediate danger of self-harm.
- 4. If unconscious but breathing, place in the recovery position.
- 5. Do not induce vomiting.
What to tell the dispatcher:
Provide the substance name (methiopropamine / MPA), estimated amount consumed, time of ingestion, route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect callers who seek help for drug-related emergencies.
Legal Status[edit]
Legal Status
MPA has been progressively controlled across major jurisdictions since its emergence on the NPS market. The WHO Expert Committee on Drug Dependence recommended placement in Schedule II of the 1971 UN Convention on Psychotropic Substances, concluding that MPA has abuse potential and ill-effects comparable to other Schedule II substances.[4]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Federally scheduled effective December 2022. Previously controlled in Florida (Schedule I, December 2012) and Arizona ("dangerous drug," April 2014)[10][21] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Temporary Class Drug Order effective 27 Nov 2015; permanent Class B under Amendment (No.2) Order 2017, effective 27 Nov 2017. Also covered by Psychoactive Substances Act 2016[3] |
| Germany | Anlage I (BtMG) | Controlled since early 2013[21] |
| China | Controlled substance | Effective 1 October 2015[21] |
| Finland | Controlled substance | Listed in government decree on narcotic substances[21] |
| Australia | Controlled substance | Listed by Office of Drug Control; specific schedule not confirmed[12] |
| Canada | Unknown | No specific scheduling information found as of 2026 |
| International | WHO ECDD Schedule II recommendation (1971 Convention) | Recommended for Schedule II placement[4] |
Analog Act Considerations
In jurisdictions where MPA is not specifically scheduled, structural analog legislation may apply. In the United States, prior to federal scheduling in December 2022, MPA could have been prosecuted under the Federal Analogue Act as a substantially similar compound to methamphetamine. Its identical side chain and similar pharmacological action would have supported such prosecution — a consideration now moot following explicit Schedule I placement.
references
- [1] ^abcdefghiTuv SS, Bergh MS, Andersen JM, Steinsland S, Vindenes V, Baumann MH, Huestis MA, Bogen IL (2021) Comparative Neuropharmacology and Pharmacokinetics of Methamphetamine and Its Thiophene Analog Methiopropamine in Rodents — International Journal of Molecular Sciences doi:10.3390/ijms222112002
- [2] ^abBunaim MK, Damanhuri HA, Yow HY, Yaakob NS, Makmor-Bakry M, Azmi N (2024) Understanding methiopropamine, a new psychoactive substance: an in-depth review on its chemistry, pharmacology and implications to human health — International Journal of Legal Medicine doi:10.1007/s00414-024-03201-7
- [3]
- [4]
- [5]
- [6]